Track the INCYTE CORPORATION stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €25.9bn. The latest transaction was filed on 19 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: PABLO CAGNONI. The full history is openly available.
11
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate INCYTE CORPORATION Buy (bullish), based on 24 analysts. Average price target: US$127.13.
29Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,452 of 29,063 companies
75.4
score / 100
Value
57
Quality
94
FCF yld5.3%
Earn yld5.1%
EV/EBITDA14.3x
ROE31%
Gross mgn93%
Net mgn25%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
2,639 shares@ US$100.00100.0% of flowCommonSEC144:0001950047-26-005611
11 of 11 declarations
Acerca de INCYTE CORPORATION
INCYTE CORPORATION es una empresa biofarmacéutica centrada en el descubrimiento y desarrollo de fármacos para el tratamiento del cáncer y enfermedades relacionadas con el sistema inmunitario. Cotiza en NASDAQ bajo el ticker INCY.